[Therapeutic results and toxic side effects of the combination cytostasan, adriamycin and vincristine as second-line therapy of metastatic breast cancer].
Remission rate of 30-50% can be obtained by different cytostatic combinations in second-line-therapy of the metastasized breast cancer. The combination of adriamycin and vincristine with cytostasan reveals a remission rate of 52% in 50 CMF-pretreated female patients. Considerable toxic side effects led to a dose reduction of cytostasan and adriamycin in 31 female patients without clinical efficiency loss. The long remission periods of the total responders (5+ -23 months) are remarkable. Both 3 female patients with bone +/- soft tissue metastasis and 3 female patients with visceral metastasis benefited from a clinical total remission. The remission rates indicated no significant differences between the group of patients with soft tissue +/- bone metastasis (56.3%) and that with a predominantly visceral metastasis (50.0%). The CyAV-combination with a low dose provides an effective therapeutical scheme with acceptable side effects for CMF-pretreated female patients with breast cancer.
Brockmann
B
B
Klinik und Poliklinik für Onkologie des Bereichs Medizin (Charité), Humboldt-Universität zu Berlin.
Kirchhof
I
I
Geschke
E
E
Schmidt
U M
UM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D009588:Nitrogen Mustard Compounds; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D005472:Fluorouracil; D008727:Methotrexate
Therapieergebnisse und toxische Nebenwirkungen der Kombination Cytostasan, Adriamycin und Vincristin als "Second line"-Therapie beim metastasierten Mammakarzinom.